Please use this identifier to cite or link to this item: http://elea.unisa.it/xmlui/handle/10556/1645

Authors:	De Biase, Chiara Capuano, Ernesto De Luca, Stefania D’Anna, Carolina Luciano, Rossella Piscione, Federico Trimarco, Bruno Galasso, Gennaro
Abstract:	Management of PCI patients undergoing early surgery is still a matter of debate. Noteworthy, PCI patients require a dual antiplatelet therapy (DAPT), with aspirine and a thienopiridine (clopidogrel, prasugrel, ticagrelor), because of the high risk of stent thrombosis (ST), myocardial infarction (MI) and death, especially within the first month. Indeed, the number of surgical interventions after PCI is actually increasing, and physicians are looking for the best antiplatelet therapy management, in order to reduce both, bleeding and thrombosis risk. In this paper, current guidelines therapy management and new optional strategies to reduce the cardiovascular risk, related to early surgery, are discussed.
Appears in Collections:	Translational Medicine @ UniSa. Volume 11 (jan.-apr. 2015)

Files in This Item:

File	Description	Size	Format
Early Surgery after Coronary Revascularization: A Fine Line between Bleeding and Thrombosis.pdf	Translational Medicine @ UniSa. Volume 11 (jan.-apr. 2015)	205,53 kB	Adobe PDF	View/Open

DSpace JSPUI